argenx SE
Latest round
- Series B
Last raised
- Nov 2013
Total raised
- $62M
Investors
- 11
About argenx SE
Founded in 2008 in Breda, Netherlands, argenx SE focuses on creating therapies for severe autoimmune diseases.00 mn.argenx specializes in the development of innovative immunology therapies, particularly focusing on severe autoimmune diseases. The company’s core product, efgartigimod, is FDA approved and marketed under the names VYVGART and VYVGART Hytrulo, specifically for treating generalized myasthenia gravis. This therapy functions by blocking the neonatal Fc receptor (FcRn), thereby reducing pathogenic immunoglobulin G (IgG) antibodies. Another significant product in their pipeline is ARGX-117, which targets the complement component C2 to address severe IgM-driven autoimmune diseases.23 bn, primarily generated through the sales of its flagship product, efgartigimod, which is offered to healthcare providers and institutions. The company is also focused on expanding its market presence in the United States and Europe, aiming to strengthen its pipeline and bring new products to market. With ongoing clinical trials and strategic initiatives, argenx is well-positioned to enhance its therapeutic offerings and enter new geographic regions, supporting its growth strategy.
Who invested in argenx SE
11 investors across 4 rounds
See all investors in argenx SE
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about argenx SE
Who invested in argenx SE?
argenx SE has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has argenx SE raised?
argenx SE has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did argenx SE last raise money?
argenx SE's most recent round on record is a Series B, in Nov 2013.
What does argenx SE do?
Founded in 2008 in Breda, Netherlands, argenx SE focuses on creating therapies for severe autoimmune diseases.
Where is argenx SE headquartered?
argenx SE is headquartered in Breda, Netherlands.
Which VCs invest in companies like argenx SE?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at argenx SE's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like argenx SE? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.